Rubin-Ehrenthal and Associates (RE&A)- Business Wire
NEW YORK--(BUSINESS WIRE)--Jan. 19, 1999--Rubin-Ehrenthal and Associates (RE&A), the consumer division of Healthworld Corporation, (NASDAQ: HWLD) has announced that a majordirect-to-consumer advertising campaign for LYMErix(TM) Lyme disease vaccine from client SmithKline Beecham, began yesterday. The product received clearance for marketing from the U.S. Food and Drug Administration on December 21, 1998. Lyme disease is the most common tick-borne illness in this country. RE&A was assigned the brand several months ago, though it was not announced until today.
Herb Ehrenthal, President of RE&A, a pioneer and leader in DTC advertising, commented, "I am extremely pleased that SmithKline Beecham, one of the world's leading healthcare companies, has committed to DTC to bring this important vaccine to the attention of the public."
Healthworld is an international marketing and communications services company specializing in healthcare. The company provides many of the world's largest pharmaceutical and other healthcare companies with a comprehensive range of integrated strategic marketing services designed to accelerate the market acceptance of new products and to sustain marketability throughout their life cycles, including advertising and promotion, contract sales, consulting, publishing, medical education, public relations, interactive multimedia, database marketing and marketing research services.
This press release contains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Those statements include statements regarding the performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements. Such risks and uncertainties include, among other things, competitive, economic and regulatory factors in the health care marketing and communications industry and the pharmaceutical and health care industry, general economic conditions, the ability of Healthworld to manage its growth and successfully implement its business strategy and other risks and uncertainties that may be detailed, from time to time, in Healthworld's reports filed with the Securities and Exchange Commission.COPYRIGHT 1999 Business Wire
Source: